Key research behind orexin and narcolepsy wins Lasker Award news2026-09-09T15:43:28+00:00September 9th, 2026|Endpoints News|
Compass posts positive psilocybin data; Solstice makes $225M debutnews2026-09-09T15:35:07+00:00September 9th, 2026|Endpoints News|
NodThera, a decade-old NLRP3 player, plans Phase 3 and a rebrandnews2026-09-09T11:01:41+00:00September 9th, 2026|Endpoints News|
Cancer biotech TwoStep gets $62.5M to take twist on ADCs into clinicnews2026-09-09T11:00:54+00:00September 9th, 2026|Endpoints News|
Kura Oncology spins out diabetes pipeline with $50M and Lilly’s helpnews2026-09-09T11:00:49+00:00September 9th, 2026|Endpoints News|
Beeline Medicines reports promising Phase 2 lupus datanews2026-09-09T11:00:48+00:00September 9th, 2026|Endpoints News|
Tyra claims Phase 2 win in bladder cancer, will advance drug to pivotal trialnews2026-09-09T11:00:08+00:00September 9th, 2026|Endpoints News|
Evommune’s MRGPRX2 antagonist flunks its second I&I trial this summernews2026-09-09T07:38:48+00:00September 9th, 2026|Endpoints News|
Current heads of CBER, CDER snag permanent jobsnews2026-09-08T21:07:50+00:00September 8th, 2026|Endpoints News|
Pharvaris’ stock jumps on pivotal success in rare genetic diseasenews2026-09-08T18:29:02+00:00September 8th, 2026|Endpoints News|
